medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2015, Número 5

Siguiente >>

Rev Invest Clin 2015; 67 (5)


Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms

Paulin F, Doyle TJ, Fletcher EA, Ascherman DP, Rosas IO

Idioma: Ingles.
Referencias bibliográficas: 56
Paginas: 280-286
Archivo PDF: 82.29 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritisinterstitial lung disease associated mortality. Am J Respir Crit Care Med. 2011;183:372-8.

  2. Zou YQ, Li YS, Ding XN, Ying ZH. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatology Intern. 2012;32:669-73.

  3. Richman NC, Yazdany J, Graf J, Chernitskiy V, Imboden JB. Extraarticular manifestations of rheumatoid arthritis in a multiethnic cohort of predominantly Hispanic and Asian patients. Medicine (Baltimore). 2013;92:92-7.

  4. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Int Med. 2008;168:159-66.

  5. Doyle TJ, Dellaripa PF, Batra K, et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014;146:41-50.

  6. BongartzT, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583-91.

  7. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.

  8. Bongartz T, Cantaert T, Atkins SR, et al. Citrullination in extraarticular manifestations of rheumatoid arthritis. Rheumatology. 2007;46:70-5.

  9. Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014; 66:813-21.

  10. Ytterberg AJ, Joshua V, Reynisdottir G, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. 2015; 74:1772-7.

  11. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoinmmune disease. Nat Rev. 2001;1:147-53.

  12. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019-27.

  13. Sivakumar P, Ntolios P, Jenkins G. Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Op Pulm Med. 2012;15:462-9.

  14. Leslie KO. Pathology of interstitial lung disease. Clin Chest Med. 2004;25:657-703.

  15. Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, traccional injury to the periphery of the aging lung. Arch Pathol Lab Med. 2012;136:591-600.

  16. Wynn TA. Fibrotic disease and the Th1/Th2 paradigm. Nat Rev Immunol. 2004;4:583-94.

  17. Selman M, Pardo A. Revealing the pathogenic an aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. Am J Resp Crit Care Med. 2013;189:1161-72.

  18. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome- wide association study. Lancet Respir Med. 2013;1:309-17.

  19. Cardenas CL, Kaminski N, Kass DJ. Micromanaging microRNAs: using murine models to study microRNAs in lung fibrosis. Drug Discov Today Dis Models. 2013;10:e145-51.

  20. Liu T, Ullenbruch M, Choi YY. Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013;49:260-8.

  21. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64:1756-61.

  22. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti- CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106:1040-7.

  23. Harlowa L, Gochuico BR, Rosas IO, et al. Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses. Clin Immunol. 2014;155:60-70.

  24. Scaly SW, Petersen J, Cheng Law S. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med. 2013;210:2569-82.

  25. Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26:64-71.

  26. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchusassociated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116:3183-94.

  27. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults and trends in smoking cessation - United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:1227-32.

  28. Evans GW, Kantrowitz E. Socioeconomic status and health: the potential role of environmental risk exposure. Annu Rev Public Health. 2002;23:303-31.

  29. House JS. Understanding social factors and inequalities in health: 20th century progress and 21st century prospects. J Health Soc Behav. 2002;43:125-42.

  30. Mathur C, Stigler MH, Perry CL, et al. Differences in prevalence of tobacco use among Indian urban youth: the role of socioeconomic status. Nicotine Tob Res. 2008;10:109-16.

  31. Baka Z, Buzás E, Nagy G. Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Res Ther. 2009;11:1-13.

  32. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginin deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67:1488-92.

  33. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322-8.

  34. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.

  35. Solomon JJ, Ryu JH, Tazelaar HD. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2013;107:1247-52.

  36. King TE, Costabel U, Cordier JF. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161:646-64.

  37. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949-61.

  38. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167:1410-15.

  39. Kim EJ, Collard HR, King Jr TE. Rheumatoid arthritis-associated interstitial lung disease: The relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397-405.

  40. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis related lung diseases: CT findings. Radiology. 2004;232:81-91.

  41. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis– associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583-8.

  42. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109-14.

  43. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185:67-76.

  44. Doyle TJ, Patel AS, Hatabu H. Detection of rheumatoid arthritisinterstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191:1403-12.

  45. Chen J, Doyle TJ, Liu Y. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67:28-38.

  46. Singh JA, Furst DE , Bharat A. Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2012;64: 625-39.

  47. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review. Semin Arthritis Rheum. 2014;43: 613-26.

  48. Nakashita T, Ando K, Kaneko N. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. BMJ Open. 2014;4:e005615

  49. Koo BS, Hong S, Kim YJ. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an antitumor necrosis factor agent. Korean J Intern Med. 2015;30: 104-9.

  50. Matteson EL, Bongartz T, Ryu JH. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis. 2012;2:53-8.

  51. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382-8.

  52. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine and N. Acetyl cytokine for pulmonary fibrosis. N Engl J Med. 2012;366:1968-77.

  53. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin. 2012;8:68-71.

  54. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011;377:1760-9.

  55. King TE, Bradford WZ, Castro Bernadini S, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.

  56. Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.




2020     |     www.medigraphic.com